This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ENDP.Q Panoramica delle azioni
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Endo Inc. Concorrenti
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.0006 |
| Massimo di 52 settimane | US$0.08 |
| Minimo di 52 settimane | US$0.000001 |
| Beta | 0.80 |
| 1Variazione di 1 mese | 50.00% |
| Variazione a 3 mesi | 0% |
| Variazione di 1 anno | -98.91% |
| 3Variazione a 3 anni | -99.99% |
| Variazione a 5 anni | -99.99% |
| Variazione dall'IPO | -100.00% |
Notizie e aggiornamenti recenti
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Rendimenti per gli azionisti
| ENDP.Q | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.3% |
| 1Y | -98.9% | 23.6% | 38.3% |
Ritorno vs Industria: ENDP.Q underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Rendimento vs Mercato: ENDP.Q underperformed the US Market which returned 22.8% over the past year.
Volatilità dei prezzi
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 207.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Prezzo delle azioni stabile: ENDP.Q's share price has been volatile over the past 3 months.
Volatilità nel tempo: ENDP.Q's weekly volatility has increased from 125% to 207% over the past year.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo Inc. Riepilogo dei fondamenti
| ENDP.Q statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$141.13k |
| Guadagni(TTM) | -US$2.45b |
| Ricavi(TTM) | US$2.01b |
0.0x
Rapporto P/S0.0x
Rapporto P/EENDP.Q è sopravvalutato?
Vedi Fair Value e analisi di valutazioneGuadagni e ricavi
| ENDP.Q Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.01b |
| Costo del fatturato | US$941.90m |
| Profitto lordo | US$1.07b |
| Altre spese | US$3.52b |
| Guadagni | -US$2.45b |
Ultimi guadagni dichiarati
Dec 31, 2023
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -10.41 |
| Margine lordo | 53.17% |
| Margine di profitto netto | -121.69% |
| Rapporto debito/patrimonio netto | -123.5% |
Come si è comportato ENDP.Q nel lungo periodo?
Vedi performance storica e confronto